Suppr超能文献

在一名病因不明的肝功能不全重症监护患者中使用CytoSorb吸附器的挑战:病例报告

Challenges in the use of the CytoSorb adsorber in an intensive care patient with liver dysfunction of unknown origin: a case report.

作者信息

Gräfe Caroline, Paal Michael, Irlbeck Michael, Liebchen Uwe, Scharf Christina, Graf Helen

机构信息

Department of Anesthesiology, LMU University Hospital Munich LMU, Marchioninistrasse 15, 81377, Munich, Germany.

Institute of Laboratory Medicine, LMU University Hospital LMU, Marchioninistr. 15, 81377, Munich, Germany.

出版信息

J Med Case Rep. 2025 Sep 8;19(1):440. doi: 10.1186/s13256-025-05503-9.

Abstract

BACKGROUND

The treatment of critically ill patients in intensive care units is becoming increasingly complex. For example, organ transplants are regularly carried out, the recipients are seriously ill, and the postoperative course can be complicated. This is why organ replacement and hemadsorption procedures are becoming increasingly important. Adsorption processes are used for specific indications, such as hyperinflammation, hepatic dysfunction, or rhabdomyolysis, in critically ill patients. Nevertheless, there is still a knowledge gap in terms of safety, interactions, and application. This case report provides an example of the thought process that went into deciding whether to apply an adsorption process, as well as other necessary treatment modifications resulting from the application.

CASE PRESENTATION

We present the case of a 26-year-old Italian man with a complicated postoperative period after lung transplant with the need of organ support systems and hemadsorption therapy. Besides operative difficulties of the transplant and massive bleeding, the patient developed a severe liver failure of unknown origin with highly elevated bile acids, which indicated the use of the CytoSorb cytokine adsorber. Since there are indications that undesired drug elimination may occur and that saturation kinetics have not yet been comprehensively investigated, there were a number of aspects to consider during application. For example, the patient received additional vancomycin dosing and vancomycin blood levels were monitored. Further, to avoid premature saturation of the adsorber, the cartridge was changed every 8 hours. These adjustments resulted in a continuous reduction in bile acids while maintaining stable vancomycin blood levels, which is critical in immunosuppressed patients.

CONCLUSION

The report focuses on two main aspects regarding a safe and sufficient usage of CytoSorb in the intensive care medicine. First, shortened changing periods increase the elimination rate of the adsorber, which is quickly saturated by bigger molecules, for example, bile acids. Second, additional vancomycin dosing during CytoSorb application avoids under dosing since CytoSorb eliminates vancomycin.

摘要

背景

重症监护病房中危重症患者的治疗日益复杂。例如,器官移植经常进行,受者病情严重,术后病程可能复杂。这就是器官替代和血液吸附程序变得越来越重要的原因。吸附过程用于危重症患者的特定适应症,如高炎症反应、肝功能障碍或横纹肌溶解。然而,在安全性、相互作用和应用方面仍存在知识空白。本病例报告提供了一个关于决定是否应用吸附过程的思维过程示例,以及应用后产生的其他必要治疗调整。

病例介绍

我们报告一例26岁意大利男性患者,肺移植术后病程复杂需器官支持系统和血液吸附治疗。除了移植手术困难和大量出血外,患者出现原因不明的严重肝功能衰竭,胆汁酸高度升高,这表明需要使用CytoSorb细胞因子吸附器。由于有迹象表明可能会发生不期望的药物清除,且尚未全面研究饱和动力学,因此在应用过程中有许多方面需要考虑。例如,患者接受了额外的万古霉素给药并监测了万古霉素血药浓度。此外,为避免吸附器过早饱和,每8小时更换一次吸附柱。这些调整导致胆汁酸持续降低,同时万古霉素血药浓度保持稳定,这对免疫抑制患者至关重要。

结论

本报告重点关注重症医学中安全充分使用CytoSorb的两个主要方面。首先,缩短更换周期可提高吸附器的清除率,吸附器会很快被大分子(如胆汁酸)饱和。其次,在应用CytoSorb期间额外给予万古霉素可避免剂量不足,因为CytoSorb会清除万古霉素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a52/12418711/2bd2a42f11ff/13256_2025_5503_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验